GT Medical Technologies, Inc. specializes in innovative treatments for patients with brain tumors, primarily through their flagship product, GammaTile Therapy. This technology is designed to be placed by neurosurgeons at the time of tumor resection, providing targeted radiation therapy that aims to delay tumor recurrence and potentially extend patient survival. One of the key advantages of GammaTile Therapy is its ability to limit radiation exposure to healthy tissue, thereby minimizing side effects such as hair loss. The therapy also ensures 100% compliance for patients, significantly reducing the burden of treatment in terms of time and travel for both patients and caregivers.

GammaTile is indicated for patients with newly diagnosed malignant intracranial neoplasms as well as those with recurrent tumors. The company emphasizes the importance of clinical resources and training for healthcare providers interested in implementing GammaTile Therapy, highlighting their commitment to improving patient outcomes in the treatment of brain tumors. Through ongoing clinical trials and the establishment of GammaTile Centers, GT Medical Technologies aims to advance the safety and efficacy of their treatment options, ultimately enhancing the quality of life for patients facing these challenging conditions.

United States

GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 1000+ patients with brain tumors.

GT Medical Technologies, Inc.

Company Details